Maryana A. Lysenko

Moscow, MOW, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Predictive value of a severity-of-illness score for toxic epidermal necrolysis (SCORTEN) factors for in-hospital mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis.

Predictive value of a severity-of-illness score for toxic epidermal necrolysis (SCORTEN) factors for in-hospital mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis.

Journal: Frontiers in medicine

Published: October 29, 2025

Chronic inducible urticaria - having more than one is common and clinically relevant.

Chronic inducible urticaria - having more than one is common and clinically relevant.

Journal: Frontiers in immunology

Published: March 18, 2025

Recurrent angioedema manifestation and treatment response in two patients from different families caring the myoferlin gene mutation: case series.

Recurrent angioedema manifestation and treatment response in two patients from different families caring the myoferlin gene mutation: case series.

Journal: Orphanet journal of rare diseases

Published: February 25, 2025

STUDY OF PREVENTION STRATEGIES FOR SIX RISK FACTORS IN REDUCING MORTALITY FROM NON-COMMUNICABLE DISEASES 25 × 25

STUDY OF PREVENTION STRATEGIES FOR SIX RISK FACTORS IN REDUCING MORTALITY FROM NON-COMMUNICABLE DISEASES 25 × 25

Journal: Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny

Published: May 15, 2024

Efficacy of dupilumab in real practice in the treatment of severe forms of asthma and atopic dermatitis (comparative retrospective study)

Efficacy of dupilumab in real practice in the treatment of severe forms of asthma and atopic dermatitis (comparative retrospective study)

Journal: Terapevticheskii arkhiv

Published: September 29, 2023

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.

Journal: Frontiers in immunology

Published: July 16, 2023

Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study

Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study

Journal: Terapevticheskii arkhiv

Published: June 29, 2023

Positive experience with TNF-α inhibitor in toxic epidermal necrolysis resistant to high-dose systemic corticosteroids.

Positive experience with TNF-α inhibitor in toxic epidermal necrolysis resistant to high-dose systemic corticosteroids.

Journal: Frontiers in medicine

Published: April 21, 2023

Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies

Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies

Journal: Terapevticheskii arkhiv

Published: February 24, 2023

SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: A clinical case.

SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: A clinical case.

Journal: Human vaccines & immunotherapeutics

Published: August 01, 2022

Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy.

Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy.

Journal: International journal of molecular sciences

Published: June 20, 2022

Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit

Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit

Journal: Terapevticheskii arkhiv

Published: June 16, 2022

Showing 1-12 of 21

Last Updated: 09/26/2026